市場調査レポート

商品コード

1403498

内分泌検査市場の2030年までの予測：検査タイプ別、技術別、エンドユーザー別、地域別の世界分析

Endocrine Testing Market Forecasts to 2030 - Global Analysis By Test Type (Human Chorionic Gonadotropin Hormone Test, Prolactin Test, Progesterone Test and Other Test Types), Technology, End User and By Geography

出版日: 2024年01月01日 | 発行: Stratistics Market Research Consulting

| ページ情報: 英文 200+ Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF (Single User License)

USD 4,150 650,554円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回のみ可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (2-5 User License)

USD 5,250 822,990円

レポートPDFを同一事業所（所在地）内の5名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF & Excel (Site License)

USD 6,350 995,426円

レポートPDFおよびExcelを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は5回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Global Site License)

USD 7,500 1,175,700円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は10回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

Stratistics MRCによると、世界の内分泌検査市場は2023年に28億米ドルを占め、予測期間中にCAGR 10.4％で成長し、2030年には55億米ドルに達すると予測されています。

内分泌検査では、体内の内分泌系におけるホルモン濃度を評価します。血液、尿、唾液サンプル中のホルモン濃度を測定することで、この診断手順はホルモンの不均衡や障害の特定を助ける。甲状腺ホルモン、コルチゾール、インスリン、テストステロンやエストロゲンなどの生殖ホルモンは、頻繁に検査されるホルモンのひとつです。

2022年3月の世界保健機関（WHO）によると、世界中で6億5,000万人の成人、3億4,000万人のティーンエイジャー、3,900万人の子供が肥満であり、その数は今も増え続けています。

ライフスタイルに関連する疾患の増加

内分泌関連疾患の増加は、座りっぱなしのライフスタイルや不健康な食習慣など、ライフスタイルパターンの変化にも一因があります。ホルモンの不均衡を正確に特定し、そのような状態の早期診断を提供できる診断検査の必要性が高まっています。さらに、内分泌検査市場は、医療専門家が生活習慣病の診断の難しさに対処するための最先端の機器を求めており、効率的な病気治療のための正確でタイムリーなホルモン評価の必要性を強調していることから、成長が見込まれています。

検体採取の誤り

正確なホルモン値測定を保証するためには、適切な検体の採取、保管、輸送が重要です。検体の不適切な取り扱い、汚染、輸送の遅れなどの問題は、検体の完全性を損ない、不正確な検査結果をもたらす可能性があります。結果のばらつきは、データ収集に一貫性のない方法を用いているヘルスケア環境の違いによっても生じる可能性があります。しかし、内分泌検査の正確性と一貫性を維持するためには、このような検体に関連する問題を解決することが不可欠であり、医療従事者に対する統一された手順とトレーニングの必要性が強調されています。

コンパニオン診断薬

コンパニオン診断薬は、内分泌疾患における個別化治療のためのテーラーメイドのソリューションを提供することで、内分泌検査市場にユニークな機会をもたらします。特定のバイオマーカーや遺伝子マーカーを同定することで、これらの診断薬は医療専門家が患者を最も適切な治療法に適合させるのを支援します。この精密なアプローチは副作用を最小化し、治療介入を最大化し、内分泌検査における治療成績を改善します。さらに、このようなカスタマイズされたアプローチは、内分泌関連ヘルスケアの一般的な有効性と経済性を高めると同時に、患者のケアを向上させる。

知的財産の課題

知的財産の問題は、新しい検査技術、バイオマーカー、診断技術の創造と応用によってもたらされます。研究開発に資金を費やす企業は、ライバルが独自の検査法を模倣したり強化しようとするかもしれないため、特許侵害を心配しなければならないです。内分泌診断学のダイナミックな性質は、既存の特許の範囲や正当性に関する問い合わせを生じさせ、知的財産権に関する紛争を引き起こします。

COVID-19の影響：

内分泌検査市場はCOVID-19の大流行によって大きな影響を受けています。内分泌系はウイルスが影響を及ぼす臓器のひとつであるため、感染者のホルモンバランスの乱れや合併症を評価する内分泌検査の必要性が高まっています。内分泌検査業界では、ウイルスがホルモンレベルに与える影響を理解するための包括的な診断ソリューションの必要性から、技術革新と研究が急増しています。内分泌疾患の診断と治療に重点が置かれているため、ヘルスケアシステムの混乱にもかかわらず、内分泌検査市場はこの困難な時期にも成長を続けています。

予測期間中はイムノアッセイ部門が最大となる見込み

イムノアッセイ分野は、ホルモンおよび関連バイオマーカーの同定における高い感度と特異性により大きく成長しています。正確で効果的な診断技術へのニーズは、糖尿病や甲状腺の問題を含む内分泌疾患の罹患率の上昇によって高まっています。さらに、自動化、新しいアッセイの開発、技術開発がこのセグメントの成長に寄与しています。

インスリン検査セグメントは予測期間中に最も高いCAGRが見込まれる

インスリン検査分野は、予測期間中に最も高いCAGRが見込まれます。糖尿病管理はインスリンレベルのモニタリングに大きく依存するため、インスリン検査は高い需要があります。この分野の成長は、より迅速で正確なアッセイなどの検査技術の発展にも助けられています。インスリン検査の採用は、個別化医療や糖尿病の早期発見が重視されるようになったことも影響しています。

最大のシェアを占める地域

内分泌疾患の有病率の増加、ホルモンの健康に対する意識の高まり、ヘルスケアインフラの進歩により、アジア太平洋地域が最大のシェアを占めています。最新の診断技術の採用やヘルスケア施設の拡大が市場の上昇に寄与しています。さらに、研究開発への投資の増加と政府の積極的な取り組みが、市場の拡大をさらに後押ししています。

CAGRが最も高い地域：

北米では内分泌疾患の罹患率が上昇し、疾患の早期発見に対する一般市民の意識が高まっているため、市場は収益性の高い成長を遂げています。同地域の高いヘルスケア支出と整備された医療インフラが市場成長をさらに刺激しています。さらに、バイオテクノロジーや製薬業界における研究開発費の増加が内分泌検査技術の革新に火をつけ、この地域の成長をさらに促進しています。

無料カスタマイズサービス：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかを提供いたします：

企業プロファイル
- 追加市場プレーヤーの包括的プロファイリング（3社まで）
- 主要企業のSWOT分析（3社まで）
地域セグメンテーション
- 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
競合ベンチマーキング
- 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

ヒト絨毛性ゴナドトロピンホルモン検査
プロラクチン検査
プロゲステロン検査
インスリン検査
甲状腺刺激ホルモン検査
黄体形成ホルモン検査
デヒドロエピアンドロステロン硫酸塩検査
エストラジオール検査
コルチゾール検査
テストステロン検査
卵胞刺激ホルモン検査
その他の検査タイプ

第6章世界の内分泌検査市場：技術別

核酸ベース
質量分析
クロマトグラフィー
免疫測定法
その他の技術

第7章世界の内分泌検査市場：エンドユーザー別

臨床検査室
診断センター
病院
その他のエンドユーザー

第8章世界の内分泌検査市場：地域別

北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- 英国
- イタリア
- フランス
- スペイン
- その他欧州
アジア太平洋地域
- 日本
- 中国
- インド
- オーストラリア
- ニュージーランド
- 韓国
- その他アジア太平洋地域
南米
- アルゼンチン
- ブラジル
- チリ
- その他南米
中東とアフリカ
- サウジアラビア
- アラブ首長国連邦
- カタール
- 南アフリカ
- その他中東とアフリカ

第9章主な発展

契約、パートナーシップ、コラボレーション、合弁事業
買収と合併
新製品の発売
事業拡大
その他の主要戦略

第10章企業プロファイル

AB Sciex
Abbott Laboratories
Agilent Technologies Inc.
Beckman Coulter, Inc.
Biomedical Technologies Limited
BioMerieux SA
Bio Rad Laboratories, Inc.
Danaher Corporation
DH Tech. Dev. Pte. Ltd.
DiaSorin SpA
F. Hoffmann-La Roche Ltd
Hologic Inc.
Laboratory Corporation of America Holdings
Ortho Clinical Diagnostics
Qiagen N.V.
Quest Diagnostics
Siemens Healthineers AG
Thermo Fisher Scientific

図表

List of Tables

Table 1 Global Endocrine Testing Market Outlook, By Region (2021-2030) ($MN)
Table 2 Global Endocrine Testing Market Outlook, By Test Type (2021-2030) ($MN)
Table 3 Global Endocrine Testing Market Outlook, By Human Chorionic Gonadotropin Hormone Test (2021-2030) ($MN)
Table 4 Global Endocrine Testing Market Outlook, By Prolactin Test (2021-2030) ($MN)
Table 5 Global Endocrine Testing Market Outlook, By Progesterone Test (2021-2030) ($MN)
Table 6 Global Endocrine Testing Market Outlook, By Insulin Test (2021-2030) ($MN)
Table 7 Global Endocrine Testing Market Outlook, By Thyroid Stimulating Hormone Test (2021-2030) ($MN)
Table 8 Global Endocrine Testing Market Outlook, By Luteinizing Hormone Test (2021-2030) ($MN)
Table 9 Global Endocrine Testing Market Outlook, By Dehydroepiandrosterone Sulfate Test (2021-2030) ($MN)
Table 10 Global Endocrine Testing Market Outlook, By Estradiol Test (2021-2030) ($MN)
Table 11 Global Endocrine Testing Market Outlook, By Cortisol Test (2021-2030) ($MN)
Table 12 Global Endocrine Testing Market Outlook, By Testosterone Test (2021-2030) ($MN)
Table 13 Global Endocrine Testing Market Outlook, By Follicle Stimulating Hormone Test (2021-2030) ($MN)
Table 14 Global Endocrine Testing Market Outlook, By Other Test Types (2021-2030) ($MN)
Table 15 Global Endocrine Testing Market Outlook, By Technology (2021-2030) ($MN)
Table 16 Global Endocrine Testing Market Outlook, By Nucleic Acid Based (2021-2030) ($MN)
Table 17 Global Endocrine Testing Market Outlook, By Mass Spectroscopy (2021-2030) ($MN)
Table 18 Global Endocrine Testing Market Outlook, By Chromatography (2021-2030) ($MN)
Table 19 Global Endocrine Testing Market Outlook, By Immunoassay (2021-2030) ($MN)
Table 20 Global Endocrine Testing Market Outlook, By Other Technologies (2021-2030) ($MN)
Table 21 Global Endocrine Testing Market Outlook, By End User (2021-2030) ($MN)
Table 22 Global Endocrine Testing Market Outlook, By Clinical Laboratories (2021-2030) ($MN)
Table 23 Global Endocrine Testing Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
Table 24 Global Endocrine Testing Market Outlook, By Hospitals (2021-2030) ($MN)
Table 25 Global Endocrine Testing Market Outlook, By Other End Users (2021-2030) ($MN)
Table 26 North America Endocrine Testing Market Outlook, By Country (2021-2030) ($MN)
Table 27 North America Endocrine Testing Market Outlook, By Test Type (2021-2030) ($MN)
Table 28 North America Endocrine Testing Market Outlook, By Human Chorionic Gonadotropin Hormone Test (2021-2030) ($MN)
Table 29 North America Endocrine Testing Market Outlook, By Prolactin Test (2021-2030) ($MN)
Table 30 North America Endocrine Testing Market Outlook, By Progesterone Test (2021-2030) ($MN)
Table 31 North America Endocrine Testing Market Outlook, By Insulin Test (2021-2030) ($MN)
Table 32 North America Endocrine Testing Market Outlook, By Thyroid Stimulating Hormone Test (2021-2030) ($MN)
Table 33 North America Endocrine Testing Market Outlook, By Luteinizing Hormone Test (2021-2030) ($MN)
Table 34 North America Endocrine Testing Market Outlook, By Dehydroepiandrosterone Sulfate Test (2021-2030) ($MN)
Table 35 North America Endocrine Testing Market Outlook, By Estradiol Test (2021-2030) ($MN)
Table 36 North America Endocrine Testing Market Outlook, By Cortisol Test (2021-2030) ($MN)
Table 37 North America Endocrine Testing Market Outlook, By Testosterone Test (2021-2030) ($MN)
Table 38 North America Endocrine Testing Market Outlook, By Follicle Stimulating Hormone Test (2021-2030) ($MN)
Table 39 North America Endocrine Testing Market Outlook, By Other Test Types (2021-2030) ($MN)
Table 40 North America Endocrine Testing Market Outlook, By Technology (2021-2030) ($MN)
Table 41 North America Endocrine Testing Market Outlook, By Nucleic Acid Based (2021-2030) ($MN)
Table 42 North America Endocrine Testing Market Outlook, By Mass Spectroscopy (2021-2030) ($MN)
Table 43 North America Endocrine Testing Market Outlook, By Chromatography (2021-2030) ($MN)
Table 44 North America Endocrine Testing Market Outlook, By Immunoassay (2021-2030) ($MN)
Table 45 North America Endocrine Testing Market Outlook, By Other Technologies (2021-2030) ($MN)
Table 46 North America Endocrine Testing Market Outlook, By End User (2021-2030) ($MN)
Table 47 North America Endocrine Testing Market Outlook, By Clinical Laboratories (2021-2030) ($MN)
Table 48 North America Endocrine Testing Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
Table 49 North America Endocrine Testing Market Outlook, By Hospitals (2021-2030) ($MN)
Table 50 North America Endocrine Testing Market Outlook, By Other End Users (2021-2030) ($MN)
Table 51 Europe Endocrine Testing Market Outlook, By Country (2021-2030) ($MN)
Table 52 Europe Endocrine Testing Market Outlook, By Test Type (2021-2030) ($MN)
Table 53 Europe Endocrine Testing Market Outlook, By Human Chorionic Gonadotropin Hormone Test (2021-2030) ($MN)
Table 54 Europe Endocrine Testing Market Outlook, By Prolactin Test (2021-2030) ($MN)
Table 55 Europe Endocrine Testing Market Outlook, By Progesterone Test (2021-2030) ($MN)
Table 56 Europe Endocrine Testing Market Outlook, By Insulin Test (2021-2030) ($MN)
Table 57 Europe Endocrine Testing Market Outlook, By Thyroid Stimulating Hormone Test (2021-2030) ($MN)
Table 58 Europe Endocrine Testing Market Outlook, By Luteinizing Hormone Test (2021-2030) ($MN)
Table 59 Europe Endocrine Testing Market Outlook, By Dehydroepiandrosterone Sulfate Test (2021-2030) ($MN)
Table 60 Europe Endocrine Testing Market Outlook, By Estradiol Test (2021-2030) ($MN)
Table 61 Europe Endocrine Testing Market Outlook, By Cortisol Test (2021-2030) ($MN)
Table 62 Europe Endocrine Testing Market Outlook, By Testosterone Test (2021-2030) ($MN)
Table 63 Europe Endocrine Testing Market Outlook, By Follicle Stimulating Hormone Test (2021-2030) ($MN)
Table 64 Europe Endocrine Testing Market Outlook, By Other Test Types (2021-2030) ($MN)
Table 65 Europe Endocrine Testing Market Outlook, By Technology (2021-2030) ($MN)
Table 66 Europe Endocrine Testing Market Outlook, By Nucleic Acid Based (2021-2030) ($MN)
Table 67 Europe Endocrine Testing Market Outlook, By Mass Spectroscopy (2021-2030) ($MN)
Table 68 Europe Endocrine Testing Market Outlook, By Chromatography (2021-2030) ($MN)
Table 69 Europe Endocrine Testing Market Outlook, By Immunoassay (2021-2030) ($MN)
Table 70 Europe Endocrine Testing Market Outlook, By Other Technologies (2021-2030) ($MN)
Table 71 Europe Endocrine Testing Market Outlook, By End User (2021-2030) ($MN)
Table 72 Europe Endocrine Testing Market Outlook, By Clinical Laboratories (2021-2030) ($MN)
Table 73 Europe Endocrine Testing Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
Table 74 Europe Endocrine Testing Market Outlook, By Hospitals (2021-2030) ($MN)
Table 75 Europe Endocrine Testing Market Outlook, By Other End Users (2021-2030) ($MN)
Table 76 Asia Pacific Endocrine Testing Market Outlook, By Country (2021-2030) ($MN)
Table 77 Asia Pacific Endocrine Testing Market Outlook, By Test Type (2021-2030) ($MN)
Table 78 Asia Pacific Endocrine Testing Market Outlook, By Human Chorionic Gonadotropin Hormone Test (2021-2030) ($MN)
Table 79 Asia Pacific Endocrine Testing Market Outlook, By Prolactin Test (2021-2030) ($MN)
Table 80 Asia Pacific Endocrine Testing Market Outlook, By Progesterone Test (2021-2030) ($MN)
Table 81 Asia Pacific Endocrine Testing Market Outlook, By Insulin Test (2021-2030) ($MN)
Table 82 Asia Pacific Endocrine Testing Market Outlook, By Thyroid Stimulating Hormone Test (2021-2030) ($MN)
Table 83 Asia Pacific Endocrine Testing Market Outlook, By Luteinizing Hormone Test (2021-2030) ($MN)
Table 84 Asia Pacific Endocrine Testing Market Outlook, By Dehydroepiandrosterone Sulfate Test (2021-2030) ($MN)
Table 85 Asia Pacific Endocrine Testing Market Outlook, By Estradiol Test (2021-2030) ($MN)
Table 86 Asia Pacific Endocrine Testing Market Outlook, By Cortisol Test (2021-2030) ($MN)
Table 87 Asia Pacific Endocrine Testing Market Outlook, By Testosterone Test (2021-2030) ($MN)
Table 88 Asia Pacific Endocrine Testing Market Outlook, By Follicle Stimulating Hormone Test (2021-2030) ($MN)
Table 89 Asia Pacific Endocrine Testing Market Outlook, By Other Test Types (2021-2030) ($MN)
Table 90 Asia Pacific Endocrine Testing Market Outlook, By Technology (2021-2030) ($MN)
Table 91 Asia Pacific Endocrine Testing Market Outlook, By Nucleic Acid Based (2021-2030) ($MN)
Table 92 Asia Pacific Endocrine Testing Market Outlook, By Mass Spectroscopy (2021-2030) ($MN)
Table 93 Asia Pacific Endocrine Testing Market Outlook, By Chromatography (2021-2030) ($MN)
Table 94 Asia Pacific Endocrine Testing Market Outlook, By Immunoassay (2021-2030) ($MN)
Table 95 Asia Pacific Endocrine Testing Market Outlook, By Other Technologies (2021-2030) ($MN)
Table 96 Asia Pacific Endocrine Testing Market Outlook, By End User (2021-2030) ($MN)
Table 97 Asia Pacific Endocrine Testing Market Outlook, By Clinical Laboratories (2021-2030) ($MN)
Table 98 Asia Pacific Endocrine Testing Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
Table 99 Asia Pacific Endocrine Testing Market Outlook, By Hospitals (2021-2030) ($MN)
Table 100 Asia Pacific Endocrine Testing Market Outlook, By Other End Users (2021-2030) ($MN)
Table 101 South America Endocrine Testing Market Outlook, By Country (2021-2030) ($MN)
Table 102 South America Endocrine Testing Market Outlook, By Test Type (2021-2030) ($MN)
Table 103 South America Endocrine Testing Market Outlook, By Human Chorionic Gonadotropin Hormone Test (2021-2030) ($MN)
Table 104 South America Endocrine Testing Market Outlook, By Prolactin Test (2021-2030) ($MN)
Table 105 South America Endocrine Testing Market Outlook, By Progesterone Test (2021-2030) ($MN)
Table 106 South America Endocrine Testing Market Outlook, By Insulin Test (2021-2030) ($MN)
Table 107 South America Endocrine Testing Market Outlook, By Thyroid Stimulating Hormone Test (2021-2030) ($MN)
Table 108 South America Endocrine Testing Market Outlook, By Luteinizing Hormone Test (2021-2030) ($MN)
Table 109 South America Endocrine Testing Market Outlook, By Dehydroepiandrosterone Sulfate Test (2021-2030) ($MN)
Table 110 South America Endocrine Testing Market Outlook, By Estradiol Test (2021-2030) ($MN)
Table 111 South America Endocrine Testing Market Outlook, By Cortisol Test (2021-2030) ($MN)
Table 112 South America Endocrine Testing Market Outlook, By Testosterone Test (2021-2030) ($MN)
Table 113 South America Endocrine Testing Market Outlook, By Follicle Stimulating Hormone Test (2021-2030) ($MN)
Table 114 South America Endocrine Testing Market Outlook, By Other Test Types (2021-2030) ($MN)
Table 115 South America Endocrine Testing Market Outlook, By Technology (2021-2030) ($MN)
Table 116 South America Endocrine Testing Market Outlook, By Nucleic Acid Based (2021-2030) ($MN)
Table 117 South America Endocrine Testing Market Outlook, By Mass Spectroscopy (2021-2030) ($MN)
Table 118 South America Endocrine Testing Market Outlook, By Chromatography (2021-2030) ($MN)
Table 119 South America Endocrine Testing Market Outlook, By Immunoassay (2021-2030) ($MN)
Table 120 South America Endocrine Testing Market Outlook, By Other Technologies (2021-2030) ($MN)
Table 121 South America Endocrine Testing Market Outlook, By End User (2021-2030) ($MN)
Table 122 South America Endocrine Testing Market Outlook, By Clinical Laboratories (2021-2030) ($MN)
Table 123 South America Endocrine Testing Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
Table 124 South America Endocrine Testing Market Outlook, By Hospitals (2021-2030) ($MN)
Table 125 South America Endocrine Testing Market Outlook, By Other End Users (2021-2030) ($MN)
Table 126 Middle East & Africa Endocrine Testing Market Outlook, By Country (2021-2030) ($MN)
Table 127 Middle East & Africa Endocrine Testing Market Outlook, By Test Type (2021-2030) ($MN)
Table 128 Middle East & Africa Endocrine Testing Market Outlook, By Human Chorionic Gonadotropin Hormone Test (2021-2030) ($MN)
Table 129 Middle East & Africa Endocrine Testing Market Outlook, By Prolactin Test (2021-2030) ($MN)
Table 130 Middle East & Africa Endocrine Testing Market Outlook, By Progesterone Test (2021-2030) ($MN)
Table 131 Middle East & Africa Endocrine Testing Market Outlook, By Insulin Test (2021-2030) ($MN)
Table 132 Middle East & Africa Endocrine Testing Market Outlook, By Thyroid Stimulating Hormone Test (2021-2030) ($MN)
Table 133 Middle East & Africa Endocrine Testing Market Outlook, By Luteinizing Hormone Test (2021-2030) ($MN)
Table 134 Middle East & Africa Endocrine Testing Market Outlook, By Dehydroepiandrosterone Sulfate Test (2021-2030) ($MN)
Table 135 Middle East & Africa Endocrine Testing Market Outlook, By Estradiol Test (2021-2030) ($MN)
Table 136 Middle East & Africa Endocrine Testing Market Outlook, By Cortisol Test (2021-2030) ($MN)
Table 137 Middle East & Africa Endocrine Testing Market Outlook, By Testosterone Test (2021-2030) ($MN)
Table 138 Middle East & Africa Endocrine Testing Market Outlook, By Follicle Stimulating Hormone Test (2021-2030) ($MN)
Table 139 Middle East & Africa Endocrine Testing Market Outlook, By Other Test Types (2021-2030) ($MN)
Table 140 Middle East & Africa Endocrine Testing Market Outlook, By Technology (2021-2030) ($MN)
Table 141 Middle East & Africa Endocrine Testing Market Outlook, By Nucleic Acid Based (2021-2030) ($MN)
Table 142 Middle East & Africa Endocrine Testing Market Outlook, By Mass Spectroscopy (2021-2030) ($MN)
Table 143 Middle East & Africa Endocrine Testing Market Outlook, By Chromatography (2021-2030) ($MN)
Table 144 Middle East & Africa Endocrine Testing Market Outlook, By Immunoassay (2021-2030) ($MN)
Table 145 Middle East & Africa Endocrine Testing Market Outlook, By Other Technologies (2021-2030) ($MN)
Table 146 Middle East & Africa Endocrine Testing Market Outlook, By End User (2021-2030) ($MN)
Table 147 Middle East & Africa Endocrine Testing Market Outlook, By Clinical Laboratories (2021-2030) ($MN)
Table 148 Middle East & Africa Endocrine Testing Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
Table 149 Middle East & Africa Endocrine Testing Market Outlook, By Hospitals (2021-2030) ($MN)
Table 150 Middle East & Africa Endocrine Testing Market Outlook, By Other End Users (2021-2030) ($MN)

Product Code: SMRC24723

According to Stratistics MRC, the Global Endocrine Testing Market is accounted for $2.8 billion in 2023 and is expected to reach $5.5 billion by 2030 growing at a CAGR of 10.4% during the forecast period. Endocrine testing involves the assessment of hormone levels in the body's endocrine system, which regulates various physiological functions. By determining the hormone concentrations in blood, urine, or saliva samples, this diagnostic procedure aids in the identification of hormonal imbalances or disorders. Thyroid hormones, cortisol, insulin, and reproductive hormones like testosterone and estrogen are among the hormones that are frequently tested.

According to the World Health Organization (WHO) in March 2022, 650 million adults, 340 million teenagers, and 39 million children are obese around the world and the number is still rising.

Market Dynamics:

Driver:

Rise in disorders associated with lifestyle

The increase in the endocrine related disorders is partly attributed to alterations in lifestyle patterns, like sedentary lifestyle and unhealthy eating habits. The need for diagnostic tests that can precisely identify hormonal imbalances and offer early diagnosis of such conditions has increased. Additionally, the market for endocrine testing is expected to grow as medical professionals look for cutting-edge instruments to handle the difficulties in diagnosing lifestyle-related illnesses, stressing the need for accurate and timely hormone evaluations for efficient illness treatment.

Restraint:

Errors in specimen collection

Appropriate specimen collection, storage, and transportation are critical to guaranteeing accurate hormone level measurements. Problems like incorrect sample handling, contamination, or transportation delays can damage the samples' integrity and produce inaccurate test results. Variability in outcomes may also be caused by different healthcare settings using inconsistent methods for data collection. However, it is imperative that these sample-related issues are resolved in order to preserve the accuracy and consistency of endocrine tests, underscoring the necessity of uniform procedures and training for healthcare personnel.

Opportunity:

Companion diagnostics

Companion diagnostics present a unique opportunity in the endocrine testing market by offering tailored solutions for personalized treatment in endocrine disorders. By identifying particular biomarkers or genetic markers, these diagnostics assist medical professionals in matching patients with the most appropriate treatments. This precision approach minimizes side effects, maximizes therapeutic interventions, and improves treatment outcomes in endocrine testing. Moreover, this customized approach enhances patient care while also adding to the general efficacy and affordability of endocrine-related healthcare.

Threat:

Intellectual property challenges

Intellectual property issues are brought about by the creation and application of novel testing techniques, biomarkers, and diagnostic technologies. Businesses that spend money on R&D have to worry about patent infringement because rivals might try to copy or enhance proprietary testing methods. The dynamic nature of endocrine diagnostics gives rise to inquiries concerning the extent and legitimacy of existing patents, thereby engendering conflicts concerning intellectual property rights.

COVID-19 Impact:

The endocrine testing market has been greatly affected by the COVID-19 pandemic. The endocrine system is one of the organs that the virus can affect, so there is a greater need for endocrine tests to evaluate hormonal imbalances and complications in infected individuals. The endocrine testing industry has seen a surge in innovation and research due to the need for comprehensive diagnostic solutions to comprehend the virus's impact on hormone levels. The focus on diagnosing and treating endocrine disorders has kept the endocrine testing market growing during these difficult times, despite disruptions in the healthcare system.

The immunoassay segment is expected to be the largest during the forecast period

The immunoassay segment has grown substantially because of its high sensitivity and specificity in identifying hormones and associated biomarkers. The need for precise and effective diagnostic techniques has been fueled by the rising incidence of endocrine disorders, including diabetes and thyroid issues. Furthermore, automation, the creation of new assays, and technological developments has all contributed to this segment's growth.

The insulin test segment is expected to have the highest CAGR during the forecast period

Insulin test segment is expected to have the highest CAGR during the forecast period. Insulin tests are in high demand because diabetes management greatly depends on insulin level monitoring. The sector's growth has also been aided by developments in testing technologies, such as faster and more accurate assays. Insulin test adoption has also been influenced by the growing emphasis on personalized medicine and the early detection of diabetes.

Region with largest share:

Asia Pacific region dominated the largest share due to the increasing prevalence of endocrine disorders, rising awareness about hormonal health, and advancements in healthcare infrastructure. The adoption of modern diagnostic technologies and the expansion of healthcare facilities contribute to the market's upward trajectory. Additionally, heightened investments in research and development, coupled with proactive government initiatives, further fuel the market's expansion.

Region with highest CAGR:

The market has grown profitably in North America due to rising incidence of endocrine disorders and increased public awareness of early disease detection. The region's high healthcare spending and well-established healthcare infrastructure have further stimulated market growth. Furthermore, increased R&D spending in the biotechnology and pharmaceutical industries has sparked innovation in endocrine testing techniques, which has further fuelled the regional growth.

Key players in the market:

Some of the key players in Endocrine Testing market include AB Sciex, Abbott Laboratories, Agilent Technologies Inc., Beckman Coulter, Inc., Biomedical Technologies Limited, BioMerieux SA, Bio Rad Laboratories, Inc. , Danaher Corporation, DH Tech. Dev. Pte. Ltd., DiaSorin SpA, F. Hoffmann-La Roche Ltd, Hologic Inc., Laboratory Corporation of America Holdings, Ortho Clinical Diagnostics, Qiagen N.V., Quest Diagnostics, Siemens Healthineers AG and Thermo Fisher Scientific.

Key Developments:

In December 2023, Roche announced the entry into a definitive merger agreement to acquire Carmot Therapeutics, Inc, a privately owned US company based in Berkeley, California. Carmot's R&D portfolio includes clinical stage subcutaneous and oral incretins with best-in-class potential to treat obesity in patients with and without diabetes, as well as a number of preclinical programs.

In May 2023, Hologic Inc., a global leader in women's health, announced a partnership with recently drafted NFL cornerback Kelee Ringo and his mother, breast cancer survivor Tralee Hale, to educate women on the importance of prioritizing annual mammograms and other key health screenings.

Test Types Covered:

Human Chorionic Gonadotropin Hormone Test
Prolactin Test
Progesterone Test
Insulin Test
Thyroid Stimulating Hormone Test
Luteinizing Hormone Test
Dehydroepiandrosterone Sulfate Test
Estradiol Test
Cortisol Test
Testosterone Test
Follicle Stimulating Hormone Test
Other Test Types

Technologies Covered:

Nucleic Acid Based
Mass Spectroscopy
Chromatography
Immunoassay
Other Technologies

End Users Covered:

Clinical Laboratories
Diagnostic Centers
Hospitals
Other End Users

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Technology Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Endocrine Testing Market, By Test Type

5.1 Introduction
5.2 Human Chorionic Gonadotropin Hormone Test
5.3 Prolactin Test
5.4 Progesterone Test
5.5 Insulin Test
5.6 Thyroid Stimulating Hormone Test
5.7 Luteinizing Hormone Test
5.8 Dehydroepiandrosterone Sulfate Test
5.9 Estradiol Test
5.10 Cortisol Test
5.11 Testosterone Test
5.12 Follicle Stimulating Hormone Test
5.13 Other Test Types

6 Global Endocrine Testing Market, By Technology

6.1 Introduction
6.2 Nucleic Acid Based
6.3 Mass Spectroscopy
6.4 Chromatography
6.5 Immunoassay
6.6 Other Technologies

7 Global Endocrine Testing Market, By End User

7.1 Introduction
7.2 Clinical Laboratories
7.3 Diagnostic Centers
7.4 Hospitals
7.5 Other End Users

8 Global Endocrine Testing Market, By Geography

8.1 Introduction
8.2 North America
- 8.2.1 US
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 Italy
- 8.3.4 France
- 8.3.5 Spain
- 8.3.6 Rest of Europe
8.4 Asia Pacific
- 8.4.1 Japan
- 8.4.2 China
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 New Zealand
- 8.4.6 South Korea
- 8.4.7 Rest of Asia Pacific
8.5 South America
- 8.5.1 Argentina
- 8.5.2 Brazil
- 8.5.3 Chile
- 8.5.4 Rest of South America
8.6 Middle East & Africa
- 8.6.1 Saudi Arabia
- 8.6.2 UAE
- 8.6.3 Qatar
- 8.6.4 South Africa
- 8.6.5 Rest of Middle East & Africa

9 Key Developments

9.1 Agreements, Partnerships, Collaborations and Joint Ventures
9.2 Acquisitions & Mergers
9.3 New Product Launch
9.4 Expansions
9.5 Other Key Strategies

10 Company Profiling

10.1 AB Sciex
10.2 Abbott Laboratories
10.3 Agilent Technologies Inc.
10.4 Beckman Coulter, Inc.
10.5 Biomedical Technologies Limited
10.6 BioMerieux SA
10.7 Bio Rad Laboratories, Inc.
10.8 Danaher Corporation
10.9 DH Tech. Dev. Pte. Ltd.
10.10 DiaSorin SpA
10.11 F. Hoffmann-La Roche Ltd
10.12 Hologic Inc.
10.13 Laboratory Corporation of America Holdings
10.14 Ortho Clinical Diagnostics
10.15 Qiagen N.V.
10.16 Quest Diagnostics
10.17 Siemens Healthineers AG
10.18 Thermo Fisher Scientific